下载 - 辅料中国

(Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis-Erfindungen
Verwaltungsgesellschaft
mbH [Novartis AG]
(Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Individual (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner);
Novartis-Erfindungen
Verwaltungsgesellschaft
mbH
(Patent
[Novartis AG]
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
Novartis AG (Patent
Assignee/Owner)
中国医药工业信息中心
数图药讯
Valsartan salts WO-00206253
( 17-JUL-2001 )
Combination of organic compounds WO-00243807
( 01-DEC-2000 )
Combination WO-00215933
( 22-AUG-2000 )
Tablet formulations comprising valsartan US-20020132839
( 22-JUN-2000 )
Pharmaceutical compositions WO-00197805
( 22-JUN-2000 )
Combination of organic compounds WO-00176574
( 12-APR-2000 )
Combination of organic compounds WO-00176573
( 12-APR-2000 )
Method for reducing pericardial fibrosis and
adhesion formation.
Use of angiotensin II receptor antagonists for
treating acute myocardial infarction
Use of AT-1 receptor antagonist or AT-2 receptor
modulator for treating diseases associated with an
increase of AT-1 or AT-2 receptors
Method of treatment and pharmaceutical
composition.
Method of treatment and pharmaceutical
composition.
US-06211217
( 16-MAR-1999 )
WO-00044378
( 26-JAN-1999 )
WO-00038676
( 23-DEC-1998 )
WO-00002543
( 10-JUL-1998 )
US-06204281
( 10-JUL-1998 )
Solid oral dosage forms of valsartan. WO-09749394
( 27-JUN-1996 )
Product
(derivative)
Component
of
Combination;
General
interest
Component
of
Combination
Formulation
Formulation
Component
of
Combination
Component
of
Combination
New use
Component
of
Combination;
New use
New use
Component
of
Combination
Component
of
Combination
Formulation
19